A pooled analysis of six month comparative efficacy and tolerability in four randomized clinical trials: agomelatine versus escitalopram, fluoxetine, and sertraline

阿戈美拉汀 依西酞普兰 中止 舍曲林 临床全球印象 耐受性 氟西汀 内科学 医学 不利影响 萧条(经济学) 抗抑郁药 血清素 安慰剂 经济 替代医学 病理 宏观经济学 海马体 受体
作者
Koen Demyttenaere,E. Corruble,Anthony S. Hale,Maria-Antonia Quera-Salva,F. Picarel-Blanchot,Siegfried Kasper
出处
期刊:CNS spectrums [Cambridge University Press]
卷期号:18 (3): 163-170 被引量:42
标识
DOI:10.1017/s1092852913000060
摘要

Objective A pooled-analysis on the long-term outcome in four head-to-head studies: agomelatine versus fluoxetine, sertraline, and (twice) escitalopram. Method A meta-analytic approach was used. Hamilton Depression Rating Scale (HAM-D) scores, response and remission rates, Clinical Global Impression of Improvement (CGI-I) scores, response and remission rates, and completion rates/discontinuation rates due to adverse events were analyzed. Results At the last post-baseline assessment on the 24-week treatment period, the final HAM-D-17 score was significantly lower in patients treated with agomelatine than in patients treated with selective serotonin reuptake inhibitors (SSRIs), as well in the total group of patients with severe depression (P = 0.014 and 0.040, respectively). HAM-D response rates at the end of 24 weeks were significantly higher in patients treated with agomelatine than in patients treated with SSRIs, as well in the total group of patients with severe depression (P = 0.031 and 0.048, respectively). HAM-D remission rates at the end of 24 weeks were numerically but not significantly higher in patients treated with agomelatine than in patients treated with SSRIs. Final CGI-I scores were significantly lower for agomelatine. CGI-I response as well as remission rates were numerically higher in patients treated with agomelatine, without statistical significance. The percentage of patients with at least one emergent adverse event leading to treatment discontinuation was 9.4% in patients treated with SSRIs and 6.6% in patients treated with agomelatine (P = 0.065). Conclusion The present pooled analysis shows that, from a clinical point of view, agomelatine is at least as efficacious as the investigated SSRIs with a trend to fewer discontinuations due to adverse events.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
眼角流星发布了新的文献求助10
刚刚
鹅蛋脸发布了新的文献求助30
2秒前
2秒前
2秒前
2秒前
2秒前
3秒前
秋风的应助被隐隐采纳,获得10
3秒前
华无剑的应助被taipingyang采纳,获得10
3秒前
斯文败类的应助被yunna_ning采纳,获得100
4秒前
Lucas的应助被李劳模采纳,获得10
4秒前
林飞发布了新的文献求助10
4秒前
奔跑的小熊完成签到 ,获得积分10
4秒前
kk的应助被ning采纳,获得10
5秒前
袁rrrr发布了新的文献求助10
5秒前
Joseph发布了新的文献求助10
5秒前
6秒前
6秒前
qqqqqqqqqq发布了新的文献求助10
6秒前
菠菜吖发布了新的文献求助10
6秒前
zyyyy完成签到,获得积分10
7秒前
8秒前
lzz完成签到,获得积分10
9秒前
李健的应助被Chllerye采纳,获得10
9秒前
9秒前
kongbin发布了新的文献求助10
9秒前
yan完成签到,获得积分20
9秒前
10秒前
10秒前
11秒前
曾业辉发布了新的文献求助10
11秒前
12秒前
12秒前
林飞完成签到,获得积分10
12秒前
秘书处堂发布了新的文献求助10
13秒前
秋风的应助被Liana_Liu采纳,获得200
13秒前
饱满向梦完成签到 ,获得积分10
13秒前
Waitcy发布了新的文献求助10
13秒前
14秒前
14秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Handbook of Sport Coaching Research 1000
Orthognathic Surgery - 2 Volume Set 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8194041
求助须知:如何正确求助?哪些是违规求助? 9579979
关于积分的说明 21868799
捐赠科研通 7793641
什么是DOI,文献DOI怎么找? 3437477
关于科研通互助平台的介绍 2560942
邀请新用户注册赠送积分活动 2484251